CAR T Cell Functionality Found to Correlate With Outcomes for Patients With NHL
April 7th 2017A retrospective analysis presented at the 2017 AACR Annual Meeting found the flexibility of CAR T cells to perform multiple functions was associated with the level of clinical activity elicited for patients with advanced non-Hodgkin’s lymphoma.
Neratinib Active in HER2-Mutated Advanced Cancers
April 5th 2017The irreversible pan-HER tyrosine kinase inhibitor neratinib showed single-agent activity across cohorts of patients with <em>HER2</em>-mutant advanced cancers, according to findings from the phase II SUMMIT study presented at the 2017 AACR Annual Meeting.
Readmission Rates Misleading in Ovarian Cancer
March 14th 2017Patients with ovarian cancer who were treated at the highest volume centers had superior overall survival but also higher readmission rates compared with lower volume hospitals, casting doubt on the value of this measure for patients with cancer.
Eribulin/Pembrolizumab Combination Active in TNBC
March 10th 2017Combining eribulin with pembrolizumab for patients with metastatic triple-negative breast cancer demonstrated promising objective response rates, including a complete response, according to findings from a phase Ib/II study presented at the 2017 Miami Breast Cancer Conference.
Dabrafenib/Trametinib Demonstrates Dramatic RFS Improvement in BRAF-Mutant Melanoma
February 8th 2017The combination of dabrafenib and trametinib before and after surgery demonstrated a dramatic improvement in relapse-free survival compared with the standard of care for patients with stage IIIb/c or oligometastatic <em>BRAF</em>-mutant melanoma.
Pembrolizumab Approved by EC for Frontline PD-L1+ Metastatic NSCLC
February 1st 2017The indication for pembrolizumab has been expanded by the European Commission to include the frontline treatment of patients with metastatic non–small cell lung cancer that expresses PD-L1 on ≥50% of cells and does not harbor an EGFR or ALK mutation.
Nab-Paclitaxel/Carboplatin Doublet Therapy Superior in Frontline TNBC Trial
January 30th 2017The risk of progression or death was reduced by 40% with the combination of nab-paclitaxel and carboplatin compared with 2 other chemotherapy doublets as a frontline therapy for patients with metastatic triple-negative breast cancer.
Two Frontline Immunotherapy Combos for NSCLC Hit With Delays
January 24th 2017Two separate delays have been announced by Bristol-Myers Squibb and AstraZeneca in the development of PD-1 and CTLA-4 inhibitor combinations as first-line therapies for patients with advanced or metastatic non–small cell lung cancer.
Encorafenib/Binimetinib a Potential New Treatment Option for BRAF-Mutant Melanoma
January 24th 2017BRAF inhibitor encorafenib combined with the MEK inhibitor binimetinib reduced the risk of progression or death by 46% compared with vemurafenib for patients with <em>BRAF</em>-mutant unresectable melanoma.
Neoadjuvant Nivolumab/Ipilimumab Shows Early Promise for Stage III Melanoma
January 23rd 2017Neoadjuvant therapy with the combination of nivolumab and ipilimumab is plausible and effective, but can induce a high level of adverse events calling for further research into better tolerated dosing schemes.
Study Results Show Nivolumab Improves Survival in Advanced Gastric/GEJ Cancer
January 20th 2017According to findings from the phase III ONO-4538-12 trial, treatment with nivolumab (Opdivo) reduced the risk of death by 37% compared with placebo for patients with advanced gastric or gastroesophageal junction (GEJ) cancer following second or later-line chemotherapy.
Frontline Pembrolizumab Combo Granted Priority Review by FDA for NSCLC
January 11th 2017A supplemental biologics license application for pembrolizumab in combination with pemetrexed plus carboplatin has been granted priority review by the FDA as a treatment for patients with metastatic or advanced non-squamous non–small cell lung cancer without <em>EGFR</em> or <em>ALK</em> mutations and regardless of PD-L1 expression.
PEGPH20 Combo Demonstrates Improved Survival in Pancreatic Cancer
January 10th 2017The combination of PEGPH20 with nab-paclitaxel and gemcitabine demonstrated improvements in progression-free survival compared with nab-paclitaxel/gemcitabine alone for untreated patients with advanced pancreatic cancer.